What are Neurocrine Biosciences's total assets?

Neurocrine Biosciences (NBIX) holds $4.9B in total assets, up 33.0% year over year.

How much debt does Neurocrine Biosciences have?

Neurocrine Biosciences carries $463.5M in total debt against $3.4B of shareholders' equity, a debt-to-equity ratio of 0.14.

How much cash does Neurocrine Biosciences have?

Neurocrine Biosciences holds $274.5M in cash and equivalents.

Can Neurocrine Biosciences cover its short-term obligations?

Its current ratio is 2.93 — current assets exceed current liabilities.

Where does Neurocrine Biosciences's balance sheet data come from?

Every line is extracted from Neurocrine Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Neurocrine Biosciences NBIX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$274.5M+35.8%	$721M+199%	$348.2M-2.5%	$272M+84.2%	$202.1M-50.0%
Short-term investments	$1.05B+40.1%	$767.4M-9.0%	$774.6M-11.9%	$711.6M-20.9%	$749.4M-8.0%
Restricted cash	——	——	——	——	——
Prepaid expenses and other current assets	$27.5M-76.9%	$21.1M-56.5%	$178.1M+46.3%	$120.7M+0.4%	$119.3M+18.7%
Income taxes receivable	——	——	——	——	——
Raw materials	$30.7M-3.8%	$35.7M+5.9%	$40.1M+69.2%	$28M+31.5%	$31.9M+76.2%
Work in process	$21.1M+52.9%	$19.2M+76.1%	$13.2M+24.5%	$15.5M+29.2%	$13.8M+15.0%
Finished goods	$12.9M-5.1%	$14.3M+11.7%	$16.2M+40.9%	$13.6M+30.8%	$13.6M+81.3%
Total current assets	$2.44B+48.7%	$2.52B+46.3%	$2.16B+15.0%	$1.75B+4.7%	$1.64B-9.0%
Property and equipment, net	$90.9M+4.5%	$89.8M+8.7%	$97.3M+21.6%	$91.7M+14.5%	$87M+15.5%
Operating lease right-of-use assets	4.9%0.0%	45,540,000,000%-5,400,000,000%	4.9%-0.1%	4.9%-0.1%	4.9%-0.2%
Deferred tax assets	$381.4M-23.6%	$320.3M-34.1%	$368.5M-18.9%	$536.8M+28.0%	$499.4M+32.0%
Other non-current assets	$20.1M-8.6%	$59.5M+14.4%	$20.2M-14.4%	$21.1M+12.2%	$22M+77.4%
Available-for-sale securities	$1.33B+63.3%	$1.06B+43.7%	$998.5M+55.1%	$873.8M+37.0%	$815.3M+16.4%
Equity securities	$146.1M+55.1%	$120.8M-3.2%	$118.1M-6.8%	$87.5M-39.1%	$94.2M-42.4%
Total assets	$4.91B+33.0%	$4.63B+24.5%	$4.27B+20.7%	$3.89B+17.7%	$3.69B+6.2%
Accounts payable	$773M+62.7%	$674.3M+46.1%	$584.3M+48.8%	$489.5M+36.5%	$475.2M+13.9%
Accrued expenses	$81.7M+42.1%	$128.8M+179%	$105.1M+36.3%	$84.6M+41.5%	$57.5M+35.0%
Operating lease liabilities, current	$57.3M+25.7%	$56M+37.9%	$51.3M+47.4%	$50.7M+43.2%	$45.6M+30.3%
Income taxes payable	$186.4M+634%	$68M-57.7%	$195.5M+44.9%	$25.7M-76.8%	$25.4M—
Accrued interest	$21.9M+51.0%	$20.5M—	$18.4M—	$16.7M—	$14.5M—
Total current liabilities	$831.7M+59.1%	$743.4M+46.4%	$638M+48.5%	$546.3M+37.1%	$522.9M-26.7%
Operating lease liabilities, non-current	$406.2M-9.2%	$415.3M-8.7%	$428.4M+70.4%	$439.1M+71.4%	$447.5M+76.9%
Operating Lease Liabilities (Total)	$463.5M-6.0%	$471.3M-4.9%	$479.7M+67.6%	$489.8M+68.0%	$493.1M+71.3%
Other non-current liabilities	$260.9M+43.7%	$219.7M+32.2%	$195.7M+45.0%	$210.1M+48.9%	$181.6M+50.7%
Total liabilities	$1.5B+30.1%	$1.38B+22.1%	$1.26B+54.7%	$1.2B+50.2%	$1.15B+6.0%
Preferred stock	$0—	$0—	$0—	$0—	$0—
Common stock	220M0.0%	220M+219,900%	220M0.0%	220M0.0%	220M0.0%
Additional paid-in capital	$2.82B+11.3%	$2.79B+9.3%	$2.7B+2.8%	$2.6B+1.6%	$2.53B+1.4%
Retained earnings	$589.6M+11,225%	$447.7M+1,433%	$294M+263%	$84.5M+274%	-$5.3M+95.3%
Accumulated other comprehensive income (loss)	$400K-95.6%	$13.1M+126%	$13.2M-9.0%	$12.5M+400%	$9M+173%
Total stockholders' equity	$3.41B+34.4%	$3.25B+25.6%	$3B+10.5%	$2.69B+7.4%	$2.54B+6.3%
Total liabilities and stockholders' equity	$4.91B+33.0%	$4.63B+24.5%	$4.27B+20.7%	$3.89B+17.7%	$3.69B+6.2%
AFS and Trading Securities - Unrealized Loss Position Fair Value	$1.58B—	$335.1M—	$349.8M—	——	——
Cash, Cash Equivalents, and Marketable Securities	$1.58B—	$335.1M—	$349.8M—	——	——
Available For Sale Securities Debt Securities Current	$1.05B+40.1%	$767.4M-9.0%	$774.6M-11.9%	$711.6M-20.9%	$749.4M-8.0%
Other current assets	$62.5M-47.6%	$115.8M+82.1%	$68.2M-44.0%	$120.7M+0.4%	$119.3M+18.7%
Operating Lease Income - 2022 (Lessor)	——	——	——	——	——
Operating Lease Income - 2025 (Lessor)	——	——	——	——	——
Operating Lease Receivables (Current)	——	——	——	——	——
Other Inventory, Net	$200K0.0%	$200K—	$200K—	$200K—	$200K—
Deferred Tax Assets and Other Non-Current Assets	$73.6M+381%	$59.5M+14.4%	$20.3M-67.0%	$21.6M-62.6%	$15.3M-69.9%
Net Investment in Lease	$20.1M-8.6%	$455.4M-10.6%	$20.2M-14.4%	$21.1M+12.2%	$22M+77.4%
Long-term marketable securities	$1.33B+63.3%	$1.06B+43.7%	$998.5M+55.1%	$873.8M+37.0%	$815.3M+16.4%
Deferred tax assets	$381.4M-23.6%	$320.3M-34.1%	$368.5M-18.9%	$536.8M+28.0%	$499.4M+32.0%
Operating lease right-of-use assets	$447.1M-11.0%	$455.4M-10.6%	$468.9M+82.2%	$492.3M+87.3%	$502.2M+85.5%
Other non-current assets	$73.6M+381%	$59.5M+14.4%	$20.3M-67.0%	$21.6M-62.6%	$15.3M-69.9%
Operating Lease Income - 2026 (Lessor)	——	——	——	——	——
Operating Lease Income - 2027 (Lessor)	——	——	——	——	——
Operating Lease Income - 2028 (Lessor)	——	——	——	——	——
Operating Lease Right-of-Use Assets in Other Assets	$447.1M-11.0%	$455.4M-10.6%	$468.9M+82.2%	$492.3M+87.3%	$502.2M+85.5%
Software and Technology Licenses, Net	$73.6M+381%	$59.5M+14.4%	$20.3M-67.0%	$21.6M-62.6%	$15.3M-69.9%
Accrued liabilities and other current	$120M+9.1%	$104.9M-4.5%	$119.9M+25.3%	$104.6M-2.4%	$110M—
Accrued Manufacturing Costs	$81.7M+42.1%	$128.8M+19.8%	$105.1M+36.3%	$84.6M+41.5%	$57.5M—
Accounts payable and other current liabilities (Note 11)	$773M+62.7%	$674.3M+46.1%	$584.3M+48.8%	$489.5M+36.5%	$475.2M+13.9%
Accrued Income Taxes, Current	——	——	——	——	——
Compensation and benefits	$81.7M+42.1%	$128.8M+19.8%	$105.1M+36.3%	$84.6M+41.5%	$57.5M—
Other accrued liabilities	$58.7M+23.1%	$69.1M+49.9%	$53.7M+45.1%	$56.8M+42.0%	$47.7M+30.0%
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——	——
Lease Liability Payments - 2021	——	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——	——
Operating Lease Liability Payments - 2026 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——	——
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	100.6M+1.6%	100.1M+0.7%	99.7M-1.5%	99M-1.9%	99M-1.6%
Convertible Preferred Stock Authorized Shares	5M0.0%	5M0.0%	5M0.0%	5M0.0%	5M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—	0—
Additional paid-in capital	$2.82B+11.3%	$2.79B+9.3%	$2.7B+2.8%	$2.6B+1.6%	$2.53B+1.4%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$100K0.0%	$100K0.0%	$100K0.0%	$100K0.0%	$100K0.0%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—
Investments - Gross Unrealized Losses	$1.58B—	$335.1M—	$349.8M—	——	——
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Unrealized Losses on Investments (Before Tax)	$7.2M—	$600K—	$500K—	——	——
Operating Lease Income - 2023 (Lessor)	——	——	——	——	——
Operating Lease Income - 2024 (Lessor)	——	——	——	——	——
Current branded prescription drug fee	$42.9M+12.9%	$45.3M-7.9%	$39M-8.7%	$38M+7.6%	$38M—
Income taxes payable – long-term	$241.3M+45.4%	$214.5M+33.5%	$195.5M+44.9%	$183M—	$166M—
Accrued development costs	$110.7M+23.4%	$101.3M+99.4%	$82.4M+115%	$61M+75.8%	$89.7M—
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$7.2M—	$600K—	$500K—	——	——
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$220M0.0%	$220M0.0%	$220M0.0%	$220M0.0%	$220M0.0%
Common stock, shares issued (in shares)	$100.6M+1.6%	$100.1M+0.7%	$99.7M-1.5%	$99M-1.9%	$99M-1.6%
Common Stock, Shares, Outstanding	$100.6M+1.6%	$100.1M+0.7%	$99.7M-1.5%	$99M-1.9%	$99M-1.6%
Debt Securities, Available-for-Sale, Unrealized Loss Position	$1.58B—	$335.1M—	$349.8M—	——	——
Raw materials	$30.7M-3.8%	$35.7M+5.9%	$40.1M+69.2%	$28M—	$31.9M—
Lessee Operating Lease Liability Payments Due	——	——	——	——	——
Thereafter	——	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——	——
Lessor, Operating Lease, Payment to be Received, after Year Four	——	——	——	——	——
Remainder of fiscal 2026	——	——	——	——	——
Operating Lease Weighted Average Discount Rate Percent	——	——	——	——	——
Other noncurrent liabilities	$19.6M—	$5.2M—	$200K—	——	——
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$5M0.0%	$5M0.0%	$5M0.0%	$5M0.0%	$5M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—	$0—
Prepaid development costs	——	——	——	——	——
Prepaid expenses	——	——	——	——	——
Provision for contract loss	$231.3M—	$226M—	$237.9M—	——	——
Remainder of Fiscal Year 2024	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Neurocrine Biosciences.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Neurocrine Biosciences's total assets?: Neurocrine Biosciences (NBIX) holds $4.9B in total assets, up 33.0% year over year.
How much debt does Neurocrine Biosciences have?: Neurocrine Biosciences carries $463.5M in total debt against $3.4B of shareholders' equity, a debt-to-equity ratio of 0.14.
How much cash does Neurocrine Biosciences have?: Neurocrine Biosciences holds $274.5M in cash and equivalents.
Can Neurocrine Biosciences cover its short-term obligations?: Its current ratio is 2.93 — current assets exceed current liabilities.
Where does Neurocrine Biosciences's balance sheet data come from?: Every line is extracted from Neurocrine Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.